ADITEC Call for EC Funded Commissioned Research
Support for Vaccine Development
Deadline: 13 November 2015 5:00 p.m. CET
Anticipated Decision Date 15 February 2016
The High Impact project on Advanced Immunization Technologies (ADITEC), funded through the 7th Framework
Programme of the European Union, aims to accelerate the development of novel and powerful immunization
technologies for the next generation of human vaccines. ADITEC is coordinated by the Sclavo Vaccines
Association (SVA): a non-profit organization that strives to ensure long-term sustainability of European vaccine
R&D efforts.
ADITEC constitutes an important cornerstone of an expanded vaccine research partnership, geared to boost
European research in the field of immunology and vaccinology. It is within this context that ADITEC will give
interested vaccine R&D users free access to consortium "in house" available vaccinology expertise and
technologies.
By facilitating better coordination among European organizations involved in vaccine research, ADITEC hopes
to expand European industry capacity in terms of vaccine R&D and production, thus promoting
competitiveness of European health industries and significantly impacting population health in the future.
Commissioned research for European Small and Medium size Enterprises (SME) and Public Health
Organizations. The ADITEC project is looking to support SMEs and public health organizations from within or
outside the ADITEC consortium in vaccine development work that will result in public health benefit. We are
actively seeking research proposals clearly aimed at vaccine development, where specific support can be
requested in the areas listed below. These services are offered by current ADITEC consortium partners and are
available free of charge to the requesting SME or public health organization, upon approval of the proposal. A
total of 1,299,878 Euros from ADITEC funding was allocated and up to 100 k€ may requested per project. The
ADITEC project will reimburse the service-providing ADITEC partners directly; no funds will be distributed to the
SME or public health organization requesting and receiving the service. There will be no cost to the awarded
SME or public health organization for the service provided. Resulting IP will be owned by the SME or public
health organization receiving the service, and maybe shared with the ADITEC partner(s) performing the
research. It will be expected that results of the "commissioned research work" will be made available to
European users, and the ADITEC support will be acknowledged. Successful external applicants, if wished so,
may apply to become an ADITEC "Affiliated Member" including all respective rights as described in the
Affiliated Member Application found on the ADITEC website. http://www.aditecproject.eu/aboutaditec/affiliated-members.html
General Application Information
For questions regarding any aspect of the submission process, please contact the ADITEC Project Manager Lynn
Zimmerman zimmerman@sclavo.org
Eligible Organizations: European SMEs and Public Health Organizations


The applicant performs the majority of its work in an institution established in a European Member State or
Associated State
Is an small or medium-sized enterprise (SME, an enterprise which employs fewer than 250 persons and has
an annual turnover not exceeding 50 million euro, and/or an annual balance sheet total not exceeding 43
million euro. For additional information on the definition of an SME, please see http://ec.europa.eu/enterprise/policies/sme/factsfigures-analysis/sme-definition/index_en.htm)


Is a Public Health Organization.
Able to commercialize or openly disseminate the results.
Applicants may submit more than one application, provided each application is scientifically distinct.
Supplemental travel and accommodation costs may be covered if the grantee is not in a position cover these
costs. In these cases, costs are only reimbursed after the expenses have been incurred and upon submission of
the requested reports and documentation. Costs must be consistent with ADITEC reimbursement guidelines
and travel dates and estimated costs must be preapproved by ADITEC management. Estimated budget must be
submitted with application.
Application Process
This form must be completed with any sections not applicable marked as such. All applications must be
completed in English and are not to exceed four pages in length including attachments. Any attachments to
your proposal must be submitted in PDF format, filenames must be included in the body of the proposal, and a
pdf extension must be used. Applications must be emailed, with the “organization’s name and Commissioned
Research Call”, in the subject line of the email. Your application will be acknowledged within 72 hours of
receiving your application.
Applications must be successfully received by Lynn Zimmerman (zimmerman@sclavo.org) and Laura Pacciarini
(pacciarini@sclavo.org) no later than 5:00 p.m. CET on 13 Nov 2015. Under no circumstances will the
Management Team accept responsibility for lost emails or consider applications received after the deadline.
Applicants are totally responsible for ensuring that their applications are received and acknowledged within the
deadline.
In its commitment to adhere to the principles of transparency, fairness and impartiality, a committee of ADITEC
partners other than those offering R&D services under the call, will be assembled to review applications both in
light of impact relevance for SMEs and public health, consistency with ADITEC programme goals and scientific
excellence. In addition, ADITEC's external advisory group will provide their recommendation on the projects to
be chosen. All applicants will be notified via email of the results of their application upon completion of the
selection process.
Other Information
Each recipient entering a support agreement will declare its commitment to deliver the reports and necessary
documentation in a Letter of Acceptance which will be issued to the User upon positive evaluation of their
proposal.
The following items are mandatory and each recipient accessing the ADITEC support services commits to
complying with the following requirements:
All reporting content and timeline requirements. This will include, but may not be limited to the submission of
organizational information to ADITEC or to the EC, a final report after awarded services are complete, a
summary report when the full project is complete and EC required impact survey. Failure to provide any report
may result in the awardee being billed for the entire cost of providing the services. The purpose of the report is
to highlight the scientific output of the services received and shall be included in the ADITEC reports to the EC.
The reports may be published on the ADITEC web site, be highlighted in the ADITEC newsletter or other ADITEC
publications. Report templates will be created and distributed at a later date.
An acknowledgement of the ADITEC project must be included in any such publications, exact wording to be
distributed at a later time. All Applicants will send full citations and full text PDF copies of all publications
resulting from or involving the work carried out under this award to the ADITEC management team. Any
subsequent publications or patents created through the support of the EC funded ADITEC project must be
communicated to the ADITEC management team.
The providers for the animal and human models will collect and submit the necessary documentations to
ethical committees and regulatory approvals. If a proposal fails to pass the ethical review the animal study
cannot be performed and has no obligation to provide the services.
To apply, please complete the following application form:
Commissioned Research
Support for Vaccine Development
Principle Investigator Name
Title
Tel.:
Mobile:
Fax: E-mail:
Name of Organization
Mailing Address
Country:
Research Project
Project Title
Project Acronym (max 20 characters)
Project Summary
Total Budget Requested
In most cases, initial discussions will need to occur with service provider to estimate
budget request
Requested Access to Service (Please check)
Please be aware that all research support offered here must be applied for specifically
as needed in the context of vaccine development. For specific questions regarding the
individual services, please contact the providers directly
Adjuvants
Evaluation of potency of new exploratory adjuvants bench-marked against the established adjuvants
systemically and/or mucosally as pertain to immune-profiling and functionality of the immune
response in mice. University of Gothenburg, A. Harandi (ali.harandi@microbio.gu.se)
21,500€/adjuvant/1 full experiment with control and bench-mark arms.
Pre-clinical QS-21 is available for use in their early vaccine formulations and GMP quality QS-21 for
human clinical trials. Desert King International (ADITEC affiliated partner), D. Hiley
(dfhiley@desertking.com).
Three independent adjuvants: sodium arsenite, gramacidine and dithiocarbonate and high
throughput template to analyse sequentially molecular interactions between any other adjuvant and
dendritic T and B cells with particular reference to the inflammasome and homeostatic pathways
leading to immunological memory. King’s College of London, T. Lehner (thomas.lehner@kcl.ac.uk).
Animal models
Mouse Model: University of Siena, D Medaglini (Medaglini@unisi.it)
Perform pre-clinical studies in the mouse model to assess the immunogenicity of vaccine
formulations and prime-boost strategies.
Chlamydia Challenge Mouse Model: Statens Serum Institut, Frank Follmann (FRF@ssi.dk)
Perform immunogenicity analysis and challenge experiment in the Chlamydia mouse model.
Immunogenicity + Challenge of a group of 12 mice. The prize includes control groups (negative /
positive). 12.000€ / vaccine group (of 10 mice) up to 4 groups
TB Challenge Mouse Model: Statens Serum Institut, Else Marie Agger (EAG@ssi.dk)
Perform immunogenicity analysis and challenge experiment in the TB mouse model.
Immunogenicity + Challenge of a group of 10 mice. The prize includes control groups (negative /
positive). 10.000€ / vaccine group (of 10 mice) up to 4 goups
Influenza Challenge Mouse Model: Imperial College London, J Tregoning
(john.tregoning@imperial.ac.uk)
Perform influenza challenge models following immunisation. Immunisation can be by various
routes, both mucosal and systemic. Infection can be with H1N1, H3N2 or B strains, enabling
homologous or heterologous infection and protection assessed by disease and viral load
measurements. Assess immunogenicity in the same animals – both antibody and cellular. N=5
mice per group, max 6 groups per study.
Animal model to assess vaccination induced cellular immune responses and immune modulation:
University Utrecht Willem van Eden (w.vaneden@uu.nl)
Perform pre-clinical studies to test vaccination induced cellular responses and immunomodulatory
activity of peptides and proteins, delivered via the intradermal route..
Groups of 10 animals with full cellular immunological monitoring following dermal vaccination.
8000€ per group
Human Trials
Human Challenge Models for Typhoid and parathyphoid vaccination/infection University of Oxford,
A. Pollard (andrew.pollard@paediatrics.ox.ac.uk).
Human Trials (including infants) for systems immunology to study transcriptome, B/T cell
immunology University of Oxford, A. Pollard (andrew.pollard@paediatrics.ox.ac.uk).
Clinical trial support from concept through to completion. Services can include: protocol design and
review, regulatory submissions and approvals, sponsorship of clinical trials, project management of
trial, pharmacovigilance and monitoring support, clinical trial delivery ,laboratory processing of
samples, data management, statistical analysis and clinical study reporting. Surrey Clinical
Research Centre, D. Lewis (D.J.Lewis@surrey.ac.uk)
MLPA Assay Reverse Transcription Multiplex Ligation-dependent Probe Amplification is high
throughput assay, which can rapidly profile mRNA expression of host. Leiden University Medical
Center, T.Ottenhoff (T.H.M.Ottenhoff@lumc.nl)
Multiplex detection of cytokine and chemokine biomarkers: evaluate the production of
cell signaling proteins, such as cytokines, chemokines, and inflammatory biomarkers in multiple
samples, using the Bio-Plex suspension array system University of Siena, A Ciabattini
(annalisa.ciabattini@unisi.it)
Formulation of vaccine antigens onto biodegradable particles: Formulate sub-unit or
vaccine components onto biodegradable particles, containing or not in their core, different immunemodulators, such as TLR or Nod ligands, by using passive adsorption process onto Poly Lactic Acid
(PLA) particles of 150<x<200nm size. CNRS, B Verrier. (bernard.verrier@ibcp.fr)
Systems biology analysis and mathematical modeling: Construction, simulation and
identification of stochastic and deterministic dynamical mathematical models of adaptive immune
response in animal models. Statistical analysis of experimental data (probability distribution function
estimation, classification, etc.). Interference of gene regulation networks. Università di Siena –
Dipartimento di Ingegneria dell’Informazione e Scienze Matematiche, A Vicino (vicino@ing.unisi.it)
Description of laboratory Please describe your laboratory and its associated facilities in relation to this
request
Relevant Publications Please list here your publications (with d.o.i) relevant to your application maximum 5 –
1.
2.
3.
4.
5.
ADITEC Project: Sclavo Vaccines Association Siena Italy Email: info@sclavo.org
http://www.aditecproject.eu/home.html